Cardiovascular Drug With Combo Effect Of Treating Diabetic Blindness Too

Overview

• Post By : Kumar Jeetendra


• Source: Queen's University


• Date: 15 Jun,2016

Researcher from Queen's University, Belfast open a mystery over drug used in cardiovascular disorders and defines dug used in cardiovascular disorder may treat diabetic blindness too.

WHO reported 422 million patients with diabetes globally and loss of vision or blindness is one of the most common problem in diabetic patients. Researcher from Queen's University in collaboration with GlaxoSmithKline done this research and found that generally used cardiovascular drug named Darapladib may reduce blindness in diabetic patients when used in the form of tablets.

With our study, we show that a blood lipid produced by Lp-PLA2 constitutes a novel trigger factor in diabetic macular edema and that use of Darapladib may not only constitute a cost-effective alternative to current DMO treatments, but has the potential to be effective for patients that currently do not respond to standard treatment." Said, Dr Patric Turowski from the UCL Institute of Ophthalmology.

Story source: Queen's University

Journal References:

Paul Canning, Bridget-Ann Kenny, Vivien Price, Josephine Glenn, Mosharraf H. Sarker, Natalie Hudson, Martin Brandt, Francisco J. Lopez, David Gale, Philip J. Luthert, Peter Adamson, Patric Turowski, Alan W. Stitt. Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes. Proceedings of the National Academy of Sciences, 2016; 201514213 DOI: 10.1073/pnas.1514213113